Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Instil Bio, Inc. (TIL)
USD7.67
-0.15 (-1.86%)
US NASDAQ Healthcare Biotechnology
Address
3963 Maple Avenue 75219
Dallas, TX, US
Dallas, TX, US
CEO
Bronson Crouch
Website
instilbio.com
IPO
2021-03-19
CIK 1789769 ISIN US45783C2008
Description
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.67
-0.15 (-1.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
25.7K
Beta
1.91
Float Shares
3.21M
Free Float %
47.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.31% | -1.22% | -9.12% | -6.05% | -36.81% | -26.64% | -52.25% | -32.88% | -97.92% | -98.47% | -98.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Hold
Price Targets & DCF
Current price
7.67
Low
7.00
-8.7%
Consensus
7.00
-8.7%
Median
7.00
-8.7%
High
7.00
-8.7%
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
7.00
-8.7%
|
| All Time | 7 |
52.71
+587.2%
|
Quality scores
Altman Z-Score
-4.40
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+6.1% Q1'26: +85.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-43.0% Q1'26: -66.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.4% ★ Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.63× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 46.0K (-100.0%)
|
—
est: 500.0K (-100.0%)
|
—
est: 3.75M (-100.0%)
|
—
est: 3.85M (-100.0%)
|
3.98M
3.98M – 3.98M
+3.3% YoY
|
8.20M
8.20M – 8.20M
+106.0% YoY
|
8.44M
8.44M – 8.44M
+3.0% YoY
|
53.80M
53.80M – 53.80M
+537.4% YoY
|
| EBITDA |
-152.51M
est: 27.6K (-552,687.0%)
|
-217.38M
est: 300.0K (-72,560.0%)
|
-62.53M
|
-52.37M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-155.27M
est: 27.6K (-562,658.0%)
|
-223.37M
est: 300.0K (-74,555.7%)
|
-66.14M
|
-52.91M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-156.79M
est: -163.08M (+3.9%)
|
-223.18M
est: -215.70M (-3.5%)
|
-74.14M
est: -84.51M (+12.3%)
|
-71.37M
est: -76.89M (+7.2%)
|
-7.80M
-7.80M – -7.80M
+89.9% YoY
|
-55.21M
-55.21M – -55.21M
-607.7% YoY
|
-73.75M
-73.75M – -73.75M
-33.6% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
51.31M
est: 995.7K (+5,053.2%)
|
62.24M
est: 10.82M (+475.1%)
|
44.21M
|
27.22M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-29.60
est: -25.05 (-18.2%)
|
-34.46
est: -33.13 (-4.0%)
|
-11.39
est: -12.72 (+10.5%)
|
-10.70
est: -11.53 (+7.2%)
|
-1.17
-1.17 – -1.17
+89.9% YoY
|
-8.28
-8.28 – -8.28
-607.7% YoY
|
-11.06
-11.06 – -11.06
-33.6% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-36.60M
OE per share TTM
-5.48
Owner's Yield
-66.38%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
477,277.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
11
Total invested
7.52M
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bronson Crouch | 43.04M | 33.60% | 2.66M | 40.38M | 2.66M | 40.38M | HC, IN | — | 2021-04-05 | ↗ |
| 2 | SB2A LP | 40.38M | 31.50% | — | 40.38M | — | 40.38M | PN | — | 2021-04-05 | ↗ |
| 3 | SB2A Management LLC | 40.38M | 31.50% | — | 40.38M | — | 40.38M | OO | — | 2021-04-05 | ↗ |
| 4 | CV-Immetacyte | 37.98M | 29.60% | — | 37.98M | — | 37.98M | OO | — | 2021-04-05 | ↗ |
| 5 | Curative Ventures V LLC | 37.98M | 29.60% | — | 37.98M | — | 37.98M | OO | — | 2021-04-05 | ↗ |
| 6 | FMR LLC | 13.19M | 10.25% | 898.9K | — | 13.19M | — | HC | Delaware | 2021-11-10 | ↗ |
| 7 | Vivo Capital IX, LLC | 12.49M | 9.70% | 12.49M | — | 12.49M | — | OO | Delaware | 2021-04-01 | ↗ |
| 8 | R. KENT MCGAUGHY, JR. | 8.53M | 6.70% | 52.0K | 8.48M | 52.0K | 8.53M | HC, IN | — | 2021-04-01 | ↗ |
| 9 | CPMG, INC. | 8.48M | 6.60% | — | 8.48M | — | 8.48M | CO | — | 2021-04-01 | ↗ |
| 10 | Peter Kolchinsky | 7.67M | 5.93% | — | 7.67M | — | — | HC, IN | Delaware | 2022-06-22 | ↗ |
| 11 | RA Capital Management, L.P. | 7.67M | 5.93% | — | 7.67M | — | — | IA, PN | Delaware | 2022-06-22 | ↗ |
| 12 | Rajeev Shah | 7.67M | 5.93% | — | 7.67M | — | — | HC, IN | Delaware | 2022-06-22 | ↗ |
| 13 | Koh, Bong | 6.87M | 5.40% | — | 6.87M | — | — | IN | United States | 2021-04-15 | ↗ |
| 14 | Shah, Nimish | 6.87M | 5.40% | — | 6.87M | — | — | IN | United States | 2021-04-15 | ↗ |
| 15 | VHCP Co-Investment Holdings II, LLC | 6.87M | 5.40% | — | 6.87M | — | — | OO | Delaware | 2021-04-15 | ↗ |
| 16 | VHCP Co-Investment Holdings III, LLC | 6.87M | 5.40% | — | 6.87M | — | — | OO | Delaware | 2021-04-15 | ↗ |
| 17 | VHCP Management EG, LLC | 6.87M | 5.40% | — | 6.87M | — | — | OO | Delaware | 2021-04-15 | ↗ |
| 18 | VHCP Management II, LLC | 6.87M | 5.40% | — | 6.87M | — | 6.87M | OO | Delaware | 2021-04-15 | ↗ |
| 19 | VHCP Management III, LLC | 6.87M | 5.40% | — | 6.87M | — | 6.87M | OO | Delaware | 2021-04-15 | ↗ |
| 20 | Venrock Healthcare Capital Partners EG, L.P. | 6.87M | 5.40% | — | 6.87M | — | — | PN | Delaware | 2021-04-15 | ↗ |
| 21 | Venrock Healthcare Capital Partners II, L.P. | 6.87M | 5.40% | — | 6.87M | — | — | PN | Delaware | 2021-04-15 | ↗ |
| 22 | Venrock Healthcare Capital Partners III, L.P. | 6.87M | 5.40% | — | 6.87M | — | — | PN | Delaware | 2021-04-15 | ↗ |
| 23 | RA Capital Healthcare Fund, L.P. | 6.66M | 5.15% | — | 6.66M | — | — | PN | Delaware | 2022-06-22 | ↗ |
| 24 | Boxer Asset Management Inc. | 355.5K | 5.50% | — | 355.5K | — | 355.5K | CO | Delaware | 2024-09-27 | ↗ |
| 25 | Joe Lewis | 355.5K | 5.50% | — | 355.5K | — | 355.5K | IN | Delaware | 2024-09-27 | ↗ |
| 26 | BML Investment Partners, L.P. | 346.2K | 5.30% | — | 346.2K | — | 346.2K | PN | Delaware | 2024-04-02 | ↗ |
| 27 | Joseph Edelman | 345.5K | 5.30% | — | 345.5K | — | 345.5K | IN | Delaware | 2024-09-27 | ↗ |
| 28 | Perceptive Advisors LLC | 345.5K | 5.30% | — | 345.5K | — | 345.5K | IA | Delaware | 2024-09-27 | ↗ |
| 29 | Perceptive Life Sciences Master Fund, Ltd. | 345.5K | 5.30% | — | 345.5K | — | 345.5K | CO | Delaware | 2024-09-27 | ↗ |
| 30 | Aaron I. Davis | 11.0K | 0.20% | — | 11.0K | — | 11.0K | IN | Delaware | 2024-09-27 | ↗ |
| 31 | MVA Investors, LLC | 11.0K | 0.20% | — | 11.0K | — | 11.0K | OO | Delaware | 2024-09-27 | ↗ |
| 32 | Boxer Capital, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2024-10-25 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
11
-17 vs prev Q
New positions
6
Closed positions
23
Increased
7
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 50.0K +50.0K (+100.0%) | 550.00M +550.0M (+100.0%) | 0.74% +0.740 pp | 0.00% +0.001 pp | USD11.00 +0.0% | 1 qtrs NEW |
| 2 | BML CAPITAL MANAGEMENT, LLC | 645.6K +— (+0.0%) | 7.10M -4.4M (-38.4%) | 9.55% -0.233 pp | 6.14% -4.419 pp | USD14.71 -25.2% | 8 qtrs — |
| 3 | CPMG INC | 410.9K +— (+0.0%) | 4.52M -2.8M (-38.4%) | 6.08% -0.148 pp | 18.33% -17.657 pp | USD7.62 +44.4% | 9 qtrs — |
| 4 | VIVO CAPITAL, LLC | 292.7K +— (+0.0%) | 3.22M -2.0M (-38.4%) | 4.33% -0.106 pp | 0.21% -0.213 pp | USD7.62 +44.4% | 9 qtrs — |
| 5 | MILLENNIUM MANAGEMENT LLC | 242.8K +46.0K (+23.4%) | 2.67M -843.3K (-24.0%) | 3.59% +0.610 pp | 0.00% 0.000 pp | USD16.53 -33.5% | 9 qtrs — |
| 6 | SIREN, L.L.C. | 203.9K +— (+0.0%) | 2.24M -1.4M (-38.4%) | 3.02% -0.074 pp | 0.07% -0.076 pp | USD64.50 -82.9% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 191.1K +23.3K (+13.9%) | 2.10M -895.4K (-29.9%) | 2.83% +0.284 pp | 0.00% +0.000 pp | USD15.73 -30.1% | 9 qtrs — |
| 8 | MORGAN STANLEY | 89.0K -14.0K (-13.6%) | 978.8K -859.7K (-46.8%) | 1.32% -0.244 pp | 0.00% 0.000 pp | USD20.03 -45.1% | 9 qtrs — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 67.8K +67.8K (+100.0%) | 745.8K +745.8K (+100.0%) | 1.00% +1.003 pp | 0.00% +0.001 pp | USD11.00 +0.0% | 9 qtrs — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 61.0K -19.8K (-24.5%) | 671.0K -772.7K (-53.5%) | 0.90% -0.322 pp | 0.00% 0.000 pp | USD24.60 -55.3% | 6 qtrs — |
| 11 | BLACKROCK, INC. | 51.2K -10.5K (-17.0%) | 563.3K -538.3K (-48.9%) | 0.76% -0.177 pp | 0.00% +0.000 pp | USD53.91 -79.6% | 6 qtrs — |
| 12 | CITADEL ADVISORS LLC | 47.3K +47.3K (+100.0%) | 520.7K +520.7K (+100.0%) | 0.70% +0.701 pp | 0.00% +0.000 pp | USD11.00 +0.0% | 1 qtrs NEW |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 42.7K +367.0 (+0.9%) | 470.0K -286.5K (-37.9%) | 0.63% -0.010 pp | 0.00% +0.000 pp | USD13.85 -20.6% | 9 qtrs — |
| 14 | QUEST PARTNERS LLC | 37.3K +22.5K (+152.8%) | 410.1K +146.7K (+55.7%) | 0.55% +0.328 pp | 0.02% +0.006 pp | USD13.85 -20.6% | 4 qtrs — |
| 15 | LPL FINANCIAL LLC | 33.1K -607.0 (-1.8%) | 363.9K -237.8K (-39.5%) | 0.49% -0.021 pp | 0.00% 0.000 pp | USD17.86 -38.4% | 2 qtrs — |
| 16 | QUADRATURE CAPITAL LTD | 19.2K +19.2K (+100.0%) | 211.2K +211.2K (+100.0%) | 0.28% +0.284 pp | 0.00% +0.002 pp | USD11.00 +0.0% | 1 qtrs NEW |
| 17 | STATE STREET CORP | 17.6K +— (+0.0%) | 193.5K -120.7K (-38.4%) | 0.26% -0.006 pp | 0.00% +0.000 pp | USD10.95 +0.5% | 9 qtrs — |
| 18 | AMERICANA PARTNERS, LLC | 16.2K +5.5K (+51.5%) | 177.9K -12.7K (-6.7%) | 0.24% +0.078 pp | 0.00% -0.001 pp | USD17.49 -37.1% | 3 qtrs — |
| 19 | XTX TOPCO LTD | 12.3K +12.3K (+100.0%) | 134.9K +134.9K (+100.0%) | 0.18% +0.182 pp | 0.00% +0.004 pp | USD11.00 +0.0% | 1 qtrs NEW |
| 20 | BARCLAYS PLC | 10.1K +10.1K (+16,808.3%) | 111.6K +107.6K (+2,662.9%) | 0.15% +0.149 pp | 0.00% +0.000 pp | USD11.04 -0.4% | 8 qtrs — |
| 21 | ROYAL BANK OF CANADA | 1.4K +1.1K (+378.3%) | 15.0K +10.0K (+200.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD13.05 -15.7% | 9 qtrs — |
| 22 | UBS GROUP AG | 359.00 -5.3K (-93.6%) | 3.9K -96.4K (-96.1%) | 0.01% -0.080 pp | 0.00% +0.000 pp | USD19.14 -42.5% | 9 qtrs — |
| 23 | RHUMBLINE ADVISERS | 114.00 +— (+0.0%) | 1.3K -782.0 (-38.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.61 +44.5% | 9 qtrs — |
| 24 | FARTHER FINANCE ADVISORS, LLC | 70.00 -41.0 (-36.9%) | 770.00 -1.2K (-61.2%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD17.84 -38.3% | 2 qtrs — |
| 25 | EQ WEALTH ADVISORS, LLC | 40.00 +40.0 (+100.0%) | 440.00 +440.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.00 +0.0% | 4 qtrs — |
| 26 | FRAZIER FINANCIAL ADVISORS, LLC | 15.00 +— (+0.0%) | 165.00 -103.0 (-38.4%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD10.53 +4.5% | 8 qtrs — |
| 27 | BNP PARIBAS ARBITRAGE, SNC | 7.00 -3.1K (-99.8%) | 77.00 -55.4K (-99.9%) | 0.00% -0.047 pp | 0.00% +0.000 pp | USD18.71 -41.2% | 8 qtrs — |
| 28 | BANK OF AMERICA CORP /DE/ | 4.00 -595.0 (-99.3%) | 44.00 -10.7K (-99.6%) | 0.00% -0.009 pp | 0.00% +0.000 pp | USD20.50 -46.3% | 9 qtrs — |
| 29 | CITIGROUP INC | — -1.0 (-100.0%) | — -18.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 30 | NORTHERN TRUST CORP | — -15.7K (-100.0%) | — -280.1K (-100.0%) | 0.00% -0.238 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 31 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -18.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 32 | SECTORAL ASSET MANAGEMENT INC | — -161.4K (-100.0%) | — -2.9M (-100.0%) | 0.00% -2.446 pp | 0.00% -1.779 pp | USD— | 3 qtrs SOLD |
| 33 | BOXER CAPITAL MANAGEMENT, LLC | — -60.7K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.920 pp | 0.00% -0.346 pp | USD— | 5 qtrs SOLD |
| 34 | BOKF, NA | — -454.0 (-100.0%) | — -8.1K (-100.0%) | 0.00% -0.007 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 35 | TOWER RESEARCH CAPITAL LLC (TRC) | — -3.1K (-100.0%) | — -56.0K (-100.0%) | 0.00% -0.048 pp | 0.00% -0.002 pp | USD— | 9 qtrs SOLD |
| 36 | FMR LLC | — -5.0 (-100.0%) | — -94.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 37 | MARSHALL WACE, LLP | — -44.9K (-100.0%) | — -801.5K (-100.0%) | 0.00% -0.680 pp | 0.00% -0.001 pp | USD— | 9 qtrs SOLD |
| 38 | JANE STREET GROUP, LLC | — -20.8K (-100.0%) | — -371.5K (-100.0%) | 0.00% -0.315 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 39 | MACQUARIE GROUP LTD | — -50.0K (-100.0%) | — -893.0K (-100.0%) | 0.00% -0.758 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 16 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 98.9K | 0.60% |
| 2 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 57.7K | 0.25% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 328.0K | 0.05% |
| 4 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 7.7K | 0.15% |
| 5 | Dimensional - US Small Cap ETF DFAS | 0.00% | 51.0K | 0.26% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 412.69 | 0.17% |
| 7 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.0K | 0.03% |
| 8 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.6K | 0.17% |
| 9 | Vanguard Total Stock Market ETF VTI | 0.00% | 955.0K | 0.03% |
| 10 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 10.7K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.50
Neutral
Buys
2
Sells
4
Shares acquired
30.0K
Shares disposed
60.0K
Cash buys
—
Cash sales
2.00
Net activity
-30,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-10 | Laumas Sandeep | Officer | M-Exempt | A | Common Stock | 13,000 | 12.68 | 164.8K | 30,000 | D | ↗ |
| 2025-05-28 | McGaughy R Kent Jr | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 26.75 | 173.9K | 6,500 | D | ↗ |
| 2025-05-28 | Matcham George | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 26.75 | 173.9K | 6,500 | D | ↗ |
| 2025-05-28 | Gibson Neil W | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 26.75 | 173.9K | 6,500 | D | ↗ |
| 2025-05-28 | Binder Gwendolyn | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 26.75 | 173.9K | 6,500 | D | ↗ |
| 2025-04-25 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 44,851 | 12.78 | 573.2K | 44,851 | D | ↗ |
| 2025-04-25 | Crouch Bronson | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 105,157 | 12.78 | 1.34M | 105,157 | D | ↗ |
| 2024-09-18 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 45,000 | 66.10 | 2.97M | 45,000 | D | ↗ |
| 2024-09-18 | Crouch Bronson | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 66.10 | 3.31M | 50,000 | D | ↗ |
| 2024-06-13 | McGaughy R Kent Jr | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 10.50 | 52.5K | 5,000 | — | ↗ |
| 2024-06-13 | Matcham George | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 10.50 | 52.5K | 5,000 | — | ↗ |
| 2024-06-13 | Gibson Neil W | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 10.50 | 52.5K | 5,000 | — | ↗ |
| 2024-06-13 | Binder Gwendolyn | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 10.50 | 52.5K | 5,000 | — | ↗ |
| 2024-02-10 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 11.60 | 928.0K | 80,000 | — | ↗ |
| 2024-02-10 | Crouch Bronson | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 11.60 | 1.39M | 120,000 | — | ↗ |
| 2023-06-14 | Nielsen Jack | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 11.18 | 16.8K | 1,500 | — | ↗ |
| 2023-06-14 | McGaughy R Kent Jr | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 11.18 | 16.8K | 1,500 | — | ↗ |
| 2023-06-14 | Matcham George | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 11.18 | 16.8K | 1,500 | — | ↗ |
| 2023-06-14 | Gibson Neil W | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 11.18 | 16.8K | 1,500 | — | ↗ |
| 2023-06-14 | Binder Gwendolyn | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 11.18 | 16.8K | 1,500 | — | ↗ |
| 2023-01-18 | Ray Sumita | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-08 | Ray Sumita | Officer | A-Award | A | Employee Stock Option (right to buy) | 415,000 | 0.00 | — | 415,000 | — | ↗ |
| 2023-01-08 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 415,000 | 0.00 | — | 415,000 | — | ↗ |
| 2023-01-08 | Crouch Bronson | Officer | A-Award | A | Employee Stock Option (right to buy) | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2022-09-06 | MOORE TIMOTHY L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 0.00 | — | 750,000 | — | ↗ |
| 2022-05-20 | Nielsen Jack | Director | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-20 | McGaughy R Kent Jr | Director | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 7.27 | 218.1K | 30,000 | — | ↗ |
| 2022-05-20 | Matcham George | Director | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-20 | Gibson Neil W | Director | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-20 | Chiruvolu Vijay | Officer | A-Award | A | Employee Stock Option (right to buy) | 154,237 | 0.00 | — | 154,237 | — | ↗ |
| 2022-05-20 | Binder Gwendolyn | Director | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-03 | Ray Sumita | Officer | — | D | Employee Stock Option (right to buy) | 425,000 | 8.40 | 3.57M | 0 | — | ↗ |
| 2022-03-15 | McGaughy R Kent Jr | Director | J-Other | D | Common Stock | 260,323 | 0.00 | — | 8,218,467 | — | ↗ |
| 2022-03-04 | Roberts Zachary | Officer | A-Award | A | Employee Stock Option (right to buy) | 245,000 | 8.62 | 2.11M | 245,000 | — | ↗ |
| 2022-03-04 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 234,000 | 0.00 | — | 234,000 | — | ↗ |
| 2022-03-04 | Crouch Bronson | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 0.00 | — | 750,000 | — | ↗ |
| 2022-03-04 | Chiruvolu Vijay | Officer | A-Award | A | Employee Stock Option (right to buy) | 257,000 | 8.62 | 2.22M | 257,000 | — | ↗ |
| 2021-10-07 | Roberts Zachary | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 0.83 | 99.6K | 240,000 | — | ↗ |
| 2021-09-10 | Roberts Zachary | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 0.83 | 99.6K | 120,000 | — | ↗ |
| 2021-05-11 | Roberts Zachary | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 16.25 | 3.25M | 200,000 | — | ↗ |
| 2021-05-11 | Laumas Sandeep | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 16.25 | 3.25M | 200,000 | — | ↗ |
| 2021-05-11 | Crouch Bronson | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 16.25 | 12.19M | 750,000 | — | ↗ |
| 2021-05-11 | Chiruvolu Vijay | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 16.25 | 3.25M | 200,000 | — | ↗ |
| 2021-04-30 | Chiruvolu Vijay | Officer | A-Award | A | Employee Stock Option (right to buy) | 154,237 | 20.53 | 3.17M | 154,237 | — | ↗ |
| 2021-03-23 | Vivo Capital IX, LLC | 10% Owner | C-Conversion | A | Common Stock | 477,091 | 0.00 | — | 12,186,787 | — | ↗ |
| 2021-03-23 | Shah Nimish P | Director | C-Conversion | A | Common Stock | 43,033 | 0.00 | — | 553,063 | — | ↗ |
| 2021-03-23 | Nielsen Jack | Director | C-Conversion | A | Common Stock | 11,709,696 | 0.00 | — | 11,709,696 | — | ↗ |
| 2021-03-23 | McGaughy R Kent Jr | Director | P-Purchase | A | Common Stock | 450,000 | 20.00 | 9.00M | 8,478,790 | — | ↗ |
| 2021-03-23 | Curative Ventures V LLC | 10% Owner | C-Conversion | D | Series C Preferred Stock | 1,192,729 | 0.00 | — | 0 | — | ↗ |
| 2021-03-23 | Crouch Bronson | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 30,000,000 | 0.00 | — | 30,000,000 | — | ↗ |
| 2021-03-18 | Vivo Capital IX, LLC | 10% Owner | — | D | Series B Preferred Stock | 11,709,696 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | Shah Nimish P | Director | — | I | Series C Preferred Stock | 480,716 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | Roberts Zachary | Officer | — | D | Employee Stock Option (right to buy) | 120,000 | 5.95 | 714.0K | 0 | — | ↗ |
| 2021-03-18 | Nielsen Jack | Director / 10% Owner | — | I | Series C Preferred Stock | 477,091 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | McGaughy R Kent Jr | Director | — | I | Series C Preferred Stock | 954,182 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | Matcham George | Director | — | D | Common Stock | 0 | 0.00 | — | 162,000 | — | ↗ |
| 2021-03-18 | Laumas Sandeep | Officer | — | D | Employee Stock Option (right to buy) | 790,000 | 0.35 | 276.5K | 0 | — | ↗ |
| 2021-03-18 | Gibson Neil W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | Curative Ventures V LLC | 10% Owner | — | — | Series B Preferred Stock | 6,098,799 | 0.00 | — | 0 | D | ↗ |
| 2021-03-18 | Crouch Bronson | Director / Officer / 10% Owner | — | D | Employee Stock Option (right to buy) | 2,922,043 | 1.15 | 3.36M | 0 | — | ↗ |
| 2021-03-18 | Chiruvolu Vijay | Officer | — | D | Employee Stock Option (right to buy) | 574,080 | 1.15 | 660.2K | 0 | — | ↗ |
| 2021-03-18 | Binder Gwendolyn | Director | A-Award | A | Stock Option (right to buy) | 52,000 | 20.00 | 1.04M | 52,000 | — | ↗ |
| 2017-01-01 | KAUTH WAYNE | Director | — | D | Restricted Voting Shares | 0 | 0.00 | — | 133,479 | — | ↗ |
| 2007-06-15 | Haigler Cliff | Officer | — | I | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.78M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Bronson Crouch Chief Executive Officer and Chairman | 740.5K | — | — | 1.08M | 421.2K | 15.2K | 2.26M | 47.84% | ↗ |
| 2 | 2025 | Sandeep Laumas Chief Financial Officer and Chief Business Officer | 528.9K | — | — | 460.4K | 231.4K | 15.2K | 1.24M | 37.25% | ↗ |
| 3 | 2024 | Bronson Crouch Chief Executive Officer and Chairman | 712.0K | 462.8K | — | 3.67M | 462.8K | 14.3K | 5.32M | 68.97% | ↗ |
| 4 | 2024 | Sandeep Laumas Chief Financial Officer and Chief Business Officer | 508.6K | 254.3K | — | 3.06M | 254.3K | 1.2K | 4.08M | 75.04% | ↗ |
| 5 | 2023 | Bronson Crouch Chief Executive Officer and Chairman | 684.7K | 423.8K | — | 437.1K | — | 13.3K | 1.56M | 28.04% | ↗ |
| 6 | 2023 | Sandeep Laumas Chief Financial Officer and Chief Business Officer | 489.0K | 232.9K | — | 181.4K | — | 1.2K | 904.5K | 20.05% | ↗ |
| 7 | 2023 | Sumita Ray Former Chief Legal, Compliance and Administrative Officer | 47.5K | — | — | 181.4K | — | 501.2K | 730.1K | 24.84% | ↗ |
| 8 | 2022 | Bronson Crouch Chief Executive Officer and Chairman | 633.6K | — | — | 4.22M | 20.5K | 18.3K | 4.89M | 86.26% | ↗ |
| 9 | 2022 | Timothy Moore Former Chief Operating Officer | 147.7K | 100.0K | — | 2.71M | — | 441.6K | 3.40M | 79.72% | ↗ |
| 10 | 2022 | Sumita Ray Former Chief Legal, Compliance and Administrative Officer | 332.9K | — | — | 2.37M | — | 109.8K | 2.81M | 84.24% | ↗ |
| 11 | 2022 | Sumita Ray Chief Legal, Compliance and Administrative Officer | 332.9K | — | — | 2.37M | — | 109.8K | 2.81M | 84.24% | ↗ |
| 12 | 2022 | Vijay Chiruvolu Former Chief Technical Officer | 336.7K | — | — | 2.19M | 11.6K | 13.5K | 2.55M | 85.81% | ↗ |
| 13 | 2022 | Sandeep Laumas Chief Financial Officer | 463.7K | — | — | 1.32M | 11.3K | 14.2K | 1.81M | 72.91% | ↗ |
| 14 | 2022 | Sandeep Laumas Chief Financial Officer and Chief Business Officer | 463.7K | — | — | 1.32M | 11.3K | 14.2K | 1.81M | 72.91% | ↗ |
| 15 | 2021 | Bronson Crouch Chief Executive Officer and Chairman | 618.3K | — | — | 34.78M | 368.6K | 11.6K | 35.78M | 97.21% | ↗ |
| 16 | 2021 | Vijay Chiruvolu Former Chief Technical Officer | 456.6K | — | — | 11.45M | 209.3K | 11.6K | 12.12M | 94.41% | ↗ |
| 17 | 2021 | Vijay Chiruvolu Chief Technical Officer | 456.6K | — | — | 11.45M | 209.3K | 11.6K | 12.12M | 94.41% | ↗ |
| 18 | 2021 | Zachary Roberts Chief Medical Officer | 462.0K | — | — | 6.16M | 309.3K | 11.6K | 6.94M | 88.72% | ↗ |
| 19 | 2020 | Bronson Crouch Chief Executive Officer and Chairman | 437.5K | — | — | 3.36M | 1.93M | 9.6K | 5.73M | 58.61% | ↗ |
| 20 | 2020 | Zachary Roberts Chief Medical Officer | 348.4K | — | — | 1.39M | 462.3K | — | 2.20M | 63.08% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bronson Crouch | Chairman & Chief Executive Officer | 1M | male |
| Sandeep Laumas | Chief Financial Officer & Chief Business Officer | 775.6K | — |
| James Freedman | Chief Medical Officer | — | — |
| Qiying Lu | Chief Medical Officer & Senior Vice President of China | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TIL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
